

# Contents

Preface	xiii
About the authors	xv
<b>Introduction</b>	<b>1</b>
<b>1 Solids</b>	<b>7</b>
1.1 Classification of solids	8
1.2 Crystalline solids: structure and properties	8
1.3 Amorphous solids	25
1.4 Dissolution of solid drugs	25
1.5 Biopharmaceutical importance of particle size	26
1.6 Wetting of powders	29
1.7 Freeze drying	32
1.8 Solid-dosage forms: formulation and manufacture	34
1.9 Solid dispersions	63
Summary	66
References	68
<b>2 Physicochemical properties of drugs in solution</b>	<b>69</b>
2.1 Concentration units	69
2.2 Thermodynamics: a brief introduction	71
2.3 Activity and chemical potential	75
2.4 Osmotic properties of drug solutions	80
2.5 Ionisation of drugs in solution	87
2.6 Diffusion of drugs in solution	105
Summary	106
References	107
<b>3 Drug stability</b>	<b>109</b>
3.1 The chemical decomposition of drugs	109
3.2 Kinetics of chemical decomposition in solution	118
3.3 Solid-dosage forms: kinetics of chemical decomposition	127
3.4 Factors influencing drug stability	129
3.5 Stability testing and prediction of shelf-life	141
Summary	149
References	150

<b>4</b>	<b>The solubility of drugs</b>	<b>153</b>
4.1	Definitions	154
4.2	Factors influencing solubility	154
4.3	Measurement of solubility	169
4.4	The solubility parameter	170
4.5	Solubility in mixed solvents: use of cosolvents	171
4.6	Cyclodextrins as solubilising agents	174
4.7	Solubility problems in formulation	177
4.8	Partitioning	181
4.9	Biological activity and partition coefficients: thermodynamic activity and Ferguson's principle	183
4.10	Using log <i>P</i>	183
	Summary	190
	References	191
<b>5</b>	<b>Surfactants</b>	<b>193</b>
5.1	Amphipathic compounds	194
5.2	Surface and interfacial properties of surfactants	195
5.3	Micellisation	218
5.4	Liquid crystals and surfactant vesicles	227
5.5	Properties of some commonly used surfactants	231
5.6	Solubilisation	237
	Summary	244
	References	244
<b>6</b>	<b>Emulsions, suspensions and related colloidal systems</b>	<b>247</b>
6.1	Colloids and their classification	248
6.2	Colloid stability	249
6.3	Disperse system flow	255
6.4	Emulsions	261
6.5	Suspensions	279
6.6	Miscellaneous colloidal systems	288
6.7	Applications of colloid stability theory to other systems	288
6.8	Foams	291
	Summary	293
	References	294
<b>7</b>	<b>Polymers and macromolecules</b>	<b>295</b>
7.1	Pharmaceutical polymers	296
7.2	Water-soluble polymers	301
7.3	General properties of polymer solutions	302
7.4	Water-soluble polymers used in pharmacy and medicine	311
7.5	Water-insoluble polymers and polymer membranes	323
7.6	Some applications of polymeric systems in drug delivery	331
	Summary	349
	References	349
	Further reading	350

<b>8</b>	<b>Drug absorption basics and the oral route</b>	<b>351</b>
8.1	Biological membranes and drug transport	352
8.2	The oral route and oral absorption	360
8.3	Oral dosage forms	365
8.4	Buccal and sublingual absorption	371
	Summary	374
	References	375
	Further reading	375
<b>9</b>	<b>Parenteral routes of drug administration</b>	<b>377</b>
9.1	Intravenous and intra-arterial administration	378
9.2	Intramuscular and subcutaneous injection	379
9.3	Transdermal delivery	386
9.4	Topical treatment of the nails: transungual therapy	397
9.5	Medication of the eye and the eye as a route for systemic delivery	398
9.6	The ear (the aural route)	406
9.7	Absorption from the vagina	407
9.8	Inhalation therapy	408
9.9	The nasal route	417
9.10	Rectal absorption of drugs	419
9.11	Drug administration to brain, spinal cord and tissues	422
	Summary	425
	References	426
<b>10</b>	<b>Paediatric and geriatric formulations</b>	<b>427</b>
10.1	Introduction	427
10.2	Paediatric medication	428
10.3	The elderly and their medication	437
	Summary	440
	References	440
<b>11</b>	<b>Physicochemical interactions and incompatibilities</b>	<b>443</b>
11.1	pH effects <i>in vitro</i> and <i>in vivo</i>	444
11.2	Dilution of mixed-solvent systems	450
11.3	Cation–anion interactions	451
11.4	Polyions and drug solutions	454
11.5	Chelation	454
11.6	Other complexes	458
11.7	Adsorption of drugs	464
11.8	Drug interactions with plastics	466
11.9	Protein binding	467
11.10	Reflections on interactions	472
	Summary	475
	Appendix: Drug interactions based on physical mechanisms	476
	References	478
	Further reading	479

<b>12</b>	<b>Adverse events: the role of formulations and delivery systems</b>	<b>481</b>
12.1	Introduction	482
12.2	Excipient effects	483
12.3	E-numbers	485
12.4	Cross-reactivity of drugs	487
12.5	Non-ionic surfactants	487
12.6	Polyoxyethylene glycols	488
12.7	Adjuvants as therapeutic substances	488
12.8	Active excipients in multiple therapies	490
12.9	Influence of dosage form type	491
12.10	Tear films and eye drops	492
12.11	Reactions to impurities	494
12.12	Crystallisation	503
12.13	Abnormal bioavailability and adverse events	504
12.14	Photochemical reactions and photoinduced reactions	506
12.15	Conclusions	509
	References	510
	Further reading	511
<b>13</b>	<b>Peptides, proteins and monoclonal antibodies</b>	<b>513</b>
13.1	Structure and solution properties of peptides and proteins	514
13.2	The stability of proteins and peptides	522
13.3	Protein formulation and delivery	527
13.4	A therapeutic protein and a peptide	534
13.5	DNA and oligonucleotides	537
13.6	Therapeutic monoclonal antibodies	538
13.7	Vaccine formulation	544
	Summary	546
	References	546
<b>14</b>	<b>Pharmaceutical nanotechnology</b>	<b>549</b>
14.1	Introduction	549
14.2	Rationale for nanoparticles for drug delivery and targeting	550
14.3	Particle structures	552
14.4	The primacy of particle size	552
14.5	Physicochemical characterisation of nanosystems	555
14.6	Preparing nanoparticles	557
14.7	Challenges in targeting	562
14.8	Detoxification: reducing blood levels	567
14.9	Regulatory challenges: characterisation	567
	Summary	568
	References	568
	Further reading	568
<b>15</b>	<b>Physical assessment of dosage forms</b>	<b>569</b>
15.1	Introduction	570

15.2	Dissolution testing of solid oral dosage forms	570
15.3	Drug release from parenteral preparations	574
15.4	Mechanical strength of tablets	577
15.5	Rheological characteristics of formulations	578
15.6	Adhesivity of dosage forms: desired and undesired	579
15.7	Mechanical strength of buccal films	582
15.8	Gastro-retentive systems: buoyancy tests	582
15.9	Evaluation of aerosols	583
	Summary	586
	References	586
	Further reading	587
<b>16</b>	<b>Generic medicines and biosimilars</b>	<b>589</b>
16.1	Introduction	590
16.2	Regulatory statements on generic products	591
16.3	Reading and deconstructing the literature on bioequivalence	594
16.4	Biosimilars: protein drugs, monoclonal antibodies	598
16.5	Conclusions	600
	References	601
	Further reading	601
	<b>Derivations</b>	<b>603</b>
	<b>Index</b>	<b>625</b>